Abcellera Biologics Stock Debt To Equity
| ABCL Stock | USD 3.27 0.13 4.14% |
Abcellera Biologics fundamentals help investors to digest information that contributes to Abcellera Biologics' financial success or failures. It also enables traders to predict the movement of Abcellera Stock. The fundamental analysis module provides a way to measure Abcellera Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abcellera Biologics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.08 | 0.07 |
Abcellera | Debt To Equity |
Abcellera Biologics Company Debt To Equity Analysis
Abcellera Biologics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Abcellera Biologics Debt To Equity | 0.06 % |
Most of Abcellera Biologics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abcellera Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Abcellera Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Abcellera Biologics is extremely important. It helps to project a fair market value of Abcellera Stock properly, considering its historical fundamentals such as Debt To Equity. Since Abcellera Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Abcellera Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Abcellera Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Abcellera Debt To Equity Historical Pattern
Today, most investors in Abcellera Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Abcellera Biologics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Abcellera Biologics debt to equity as a starting point in their analysis.
Abcellera Biologics Debt To Equity |
| Timeline |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Abcellera Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Abcellera Biologics has a Debt To Equity of 0.06%. This is 99.89% lower than that of the Biotechnology sector and 99.69% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.88% higher than that of the company.
Abcellera Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abcellera Biologics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abcellera Biologics could also be used in its relative valuation, which is a method of valuing Abcellera Biologics by comparing valuation metrics of similar companies.Abcellera Biologics is currently under evaluation in debt to equity category among its peers.
Abcellera Biologics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Abcellera Biologics from analyzing Abcellera Biologics' financial statements. These drivers represent accounts that assess Abcellera Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Abcellera Biologics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 10.8B | 3.9B | 2.9B | 1.7B | 1.9B | 1.8B | |
| Enterprise Value | 10.3B | 3.5B | 2.6B | 1.6B | 1.8B | 1.7B |
Abcellera Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Abcellera Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Abcellera Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Abcellera Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (14.39) % | ||||
| Current Valuation | 394.11 M | ||||
| Shares Outstanding | 295.37 M | ||||
| Shares Owned By Insiders | 23.07 % | ||||
| Shares Owned By Institutions | 42.93 % | ||||
| Number Of Shares Shorted | 18.43 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 29.30 X | ||||
| Revenue | 38.02 M | ||||
| Gross Profit | (136.84 M) | ||||
| EBITDA | (192.16 M) | ||||
| Net Income | (146.4 M) | ||||
| Cash And Equivalents | 868.21 M | ||||
| Cash Per Share | 3.04 X | ||||
| Total Debt | 77.38 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 3.65 X | ||||
| Cash Flow From Operations | (43.88 M) | ||||
| Short Ratio | 4.77 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Price To Earnings To Growth | 2.22 X | ||||
| Target Price | 12.14 | ||||
| Number Of Employees | 586 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 965.85 M | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 279.79 M | ||||
| Working Capital | 752.97 M | ||||
| Net Asset | 1.49 B |
About Abcellera Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abcellera Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abcellera Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abcellera Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Abcellera Biologics Piotroski F Score and Abcellera Biologics Altman Z Score analysis. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.